Orchid Pharma Limited (ORCHPHARMA.NS)
INR 1794.0
(0.9%)
INR 1794.0
(0.9%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.2 Billion INR | -19.09% |
| 2022 | 1.48 Billion INR | -28.5% |
| 2021 | 2.08 Billion INR | -51.31% |
| 2020 | 4.27 Billion INR | -14.75% |
| 2019 | 5.01 Billion INR | -64.8% |
| 2018 | 14.24 Billion INR | -24.78% |
| 2017 | 18.93 Billion INR | -12.19% |
| 2016 | 21.56 Billion INR | -9.29% |
| 2015 | 23.77 Billion INR | -4.67% |
| 2014 | 24.93 Billion INR | 176.55% |
| 2013 | 9.01 Billion INR | 0.0% |
| 2011 | 10.74 Billion INR | -19.35% |
| 2010 | 13.31 Billion INR | 28.58% |
| 2009 | 10.35 Billion INR | -43.21% |
| 2008 | 18.24 Billion INR | 53.35% |
| 2007 | 11.89 Billion INR | 49.34% |
| 2006 | 7.96 Billion INR | -23.77% |
| 2005 | 10.44 Billion INR | 3.96% |
| 2004 | 10.05 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 1.2 Billion INR | -19.09% |
| 2023 Q2 | 1.37 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.2 Billion INR | 0.0% |
| 2022 Q2 | 2.08 Billion INR | 0.0% |
| 2022 Q4 | 1.48 Billion INR | 0.0% |
| 2022 FY | 1.48 Billion INR | -28.5% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 2.08 Billion INR | -51.31% |
| 2021 Q4 | 2.08 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.56 Billion INR | 0.0% |
| 2020 Q2 | 4.32 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 4.27 Billion INR | 0.0% |
| 2020 FY | 4.27 Billion INR | -14.75% |
| 2020 Q1 | - INR | -100.0% |
| 2019 FY | 5.01 Billion INR | -64.8% |
| 2019 Q4 | 5.01 Billion INR | 0.0% |
| 2019 Q1 | - INR | 0.0% |
| 2018 FY | 14.24 Billion INR | -24.78% |
| 2018 Q2 | 17.81 Billion INR | 0.0% |
| 2017 FY | 18.93 Billion INR | -12.19% |
| 2016 FY | 21.56 Billion INR | -9.29% |
| 2015 FY | 23.77 Billion INR | -4.67% |
| 2014 FY | 24.93 Billion INR | 176.55% |
| 2013 FY | 9.01 Billion INR | 0.0% |
| 2013 Q2 | 9.01 Billion INR | 0.0% |
| 2011 FY | 10.74 Billion INR | -19.35% |
| 2011 Q4 | 10.74 Billion INR | 0.0% |
| 2010 FY | 13.31 Billion INR | 28.58% |
| 2009 FY | 10.35 Billion INR | -43.21% |
| 2008 FY | 18.24 Billion INR | 53.35% |
| 2007 FY | 11.89 Billion INR | 49.34% |
| 2006 FY | 7.96 Billion INR | -23.77% |
| 2005 FY | 10.44 Billion INR | 3.96% |
| 2004 FY | 10.05 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 265.79 Million INR | -353.088% |
| Ind-Swift Limited | 10.09 Billion INR | 88.07% |
| Bajaj HealthCare Limited | 650.34 Million INR | -85.178% |
| Sakar Healthcare Limited | 549.55 Million INR | -119.143% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 94.359% |
| Innova Captab Limited | 2.1 Billion INR | 42.794% |
| Divi's Laboratories Limited | 20 Million INR | -5921.49% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -4226.405% |
| Morepen Laboratories Limited | 33.64 Million INR | -3479.958% |
| Mankind Pharma Limited | 325.81 Million INR | -269.626% |
| Sequent Scientific Limited | 1.42 Billion INR | 15.618% |
| Wanbury Limited | 820 Million INR | -46.866% |
| Laurus Labs Limited | 7.98 Billion INR | 84.913% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 14.168% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -715.865% |
| Alembic Limited | 73.9 Million INR | -1529.632% |
| Hikal Limited | 4.22 Billion INR | 71.519% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | -91.523% |
| Neuland Laboratories Limited | 449.2 Million INR | -168.095% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -409.432% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 20.608% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Themis Medicare Limited | 267.74 Million INR | -349.801% |
| RPG Life Sciences Limited | -30.3 Million INR | 4074.581% |
| Zydus Lifesciences Limited | 251 Million INR | -379.8% |
| Lupin Limited | 1.55 Billion INR | 22.443% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -8521.836% |
| Wockhardt Limited | 8.91 Billion INR | 86.484% |
| Vaishali Pharma Limited | 35.98 Million INR | -3246.853% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -300974.5% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -1493.619% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 96.197% |
| FDC Limited | 2.46 Million INR | -48736.091% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 79.895% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Eris Lifesciences Limited | 6.54 Billion INR | 81.6% |
| Venus Remedies Limited | 386.8 Million INR | -211.349% |
| ZIM Laboratories Limited | 356 Million INR | -238.28% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -238.36% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 9.2 Million INR | -12990.196% |
| Shilpa Medicare Limited | 5.6 Billion INR | 78.501% |
| Albert David Limited | 6.01 Million INR | -19918.251% |
| Ajanta Pharma Limited | 235.2 Million INR | -412.031% |
| Hester Biosciences Limited | 1.81 Billion INR | 33.747% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -467.113% |
| Solara Active Pharma Sciences Limited | 1.17 Billion INR | -2.546% |
| Gufic Biosciences Limited | 1.53 Billion INR | 21.78% |
| Windlas Biotech Limited | 20.18 Million INR | -5867.78% |
| Procter & Gamble Health Limited | 68.8 Million INR | -1650.433% |
| Aarey Drugs & Pharmaceuticals Limited | 32.24 Million INR | -3634.979% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -801.819% |
| Granules India Limited | 689.71 Million INR | -74.609% |
| Aarti Drugs Limited | 2.75 Billion INR | 56.26% |
| Bal Pharma Limited | 363.82 Million INR | -231.011% |
| Alkem Laboratories Limited | 400 Million INR | -201.075% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -8954.872% |
| Lincoln Pharmaceuticals Limited | - INR | -Infinity% |
| Medicamen Biotech Limited | 12.55 Million INR | -9492.178% |
| Unichem Laboratories Limited | 382.22 Million INR | -215.079% |
| Bafna Pharmaceuticals Limited | 107.53 Million INR | -1019.944% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Valiant Laboratories Limited | 750.89 Million INR | -60.381% |
| Medico Remedies Limited | 8.67 Million INR | -13787.2% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -978.869% |
| Ipca Laboratories Limited | 5.8 Billion INR | 79.251% |
| Brooks Laboratories Limited | 3.56 Million INR | -33681.15% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 98893.929% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.775% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 92.492% |
| NATCO Pharma Limited | 53 Million INR | -2172.26% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 34.371% |
| Strides Pharma Science Limited | 6.71 Billion INR | 82.066% |
| Indoco Remedies Limited | 3.51 Billion INR | 65.761% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -1029.735% |